File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity
  • Basic View
  • Metadata View
  • XML View
TitleA 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity
 
AuthorsDu, L3
Zhao, G1 2
Chan, CC2
Li, L3
He, Y3
Zhou, Y1
Zheng, BJ2
Jiang, S3
 
Issue Date2010
 
PublisherMary Ann Liebert, Inc Publishers. The Journal's web site is located at http://www.liebertpub.com/vim
 
CitationViral Immunology, 2010, v. 23 n. 2, p. 211-219 [How to Cite?]
DOI: http://dx.doi.org/10.1089/vim.2009.0090
 
AbstractDevelopment of vaccines is essential for the prevention of future recurrences of severe acute respiratory syndrome (SARS), caused by the SARS coronavirus (SARS-CoV). The spike (S) protein, especially receptor-binding domain (RBD) of SARS-CoV, plays important roles in the prevention of SARS infection, and is thus an important component in SARS vaccine development. In this study, we expressed a 219-mer (residues 318-536) RBD protein in Chinese hamster ovary (CHO)-K1 cells (RBD219-CHO), and tested its immune responses and protective immunity in a mouse model. The results showed that this recombinant protein was correctly folded, being able to maintain intact conformation and authentic antigenicity. It could induce strong humoral and cellular immune responses and high titers of neutralizing antibodies in the vaccinated mice. RBD219-CHO protein elicited potent protective immunity that protected all vaccinated mice from SARS-CoV challenge. These results suggest that the recombinant RBD219-CHO protein has great potential for the development of an effective and safe SARS subunit vaccine. © Copyright 2010, Mary Ann Liebert, Inc..
 
ISSN0882-8245
2013 Impact Factor: 1.636
 
DOIhttp://dx.doi.org/10.1089/vim.2009.0090
 
PubMed Central IDPMC2883479
 
ISI Accession Number IDWOS:000276413200010
Funding AgencyGrant Number
National Institutes of Health (NIH)RO1 AI68002
Hong Kong SAR Government
National 973 Basic Research Program of China2005CB523001
Funding Information:

This study was supported by the National Institutes of Health (NIH) of the United States (RO1 AI68002), by the Research Fund for the Control of Infectious Diseases, the Health, Welfare and Food Bureau of the Hong Kong SAR Government, and by the National 973 Basic Research Program of China (2005CB523001).

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorDu, L
 
dc.contributor.authorZhao, G
 
dc.contributor.authorChan, CC
 
dc.contributor.authorLi, L
 
dc.contributor.authorHe, Y
 
dc.contributor.authorZhou, Y
 
dc.contributor.authorZheng, BJ
 
dc.contributor.authorJiang, S
 
dc.date.accessioned2010-10-31T11:14:27Z
 
dc.date.available2010-10-31T11:14:27Z
 
dc.date.issued2010
 
dc.description.abstractDevelopment of vaccines is essential for the prevention of future recurrences of severe acute respiratory syndrome (SARS), caused by the SARS coronavirus (SARS-CoV). The spike (S) protein, especially receptor-binding domain (RBD) of SARS-CoV, plays important roles in the prevention of SARS infection, and is thus an important component in SARS vaccine development. In this study, we expressed a 219-mer (residues 318-536) RBD protein in Chinese hamster ovary (CHO)-K1 cells (RBD219-CHO), and tested its immune responses and protective immunity in a mouse model. The results showed that this recombinant protein was correctly folded, being able to maintain intact conformation and authentic antigenicity. It could induce strong humoral and cellular immune responses and high titers of neutralizing antibodies in the vaccinated mice. RBD219-CHO protein elicited potent protective immunity that protected all vaccinated mice from SARS-CoV challenge. These results suggest that the recombinant RBD219-CHO protein has great potential for the development of an effective and safe SARS subunit vaccine. © Copyright 2010, Mary Ann Liebert, Inc..
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationViral Immunology, 2010, v. 23 n. 2, p. 211-219 [How to Cite?]
DOI: http://dx.doi.org/10.1089/vim.2009.0090
 
dc.identifier.doihttp://dx.doi.org/10.1089/vim.2009.0090
 
dc.identifier.epage219
 
dc.identifier.hkuros175102
 
dc.identifier.isiWOS:000276413200010
Funding AgencyGrant Number
National Institutes of Health (NIH)RO1 AI68002
Hong Kong SAR Government
National 973 Basic Research Program of China2005CB523001
Funding Information:

This study was supported by the National Institutes of Health (NIH) of the United States (RO1 AI68002), by the Research Fund for the Control of Infectious Diseases, the Health, Welfare and Food Bureau of the Hong Kong SAR Government, and by the National 973 Basic Research Program of China (2005CB523001).

 
dc.identifier.issn0882-8245
2013 Impact Factor: 1.636
 
dc.identifier.issue2
 
dc.identifier.openurl
 
dc.identifier.pmcidPMC2883479
 
dc.identifier.pmid20374001
 
dc.identifier.scopuseid_2-s2.0-77953940733
 
dc.identifier.spage211
 
dc.identifier.urihttp://hdl.handle.net/10722/125154
 
dc.identifier.volume23
 
dc.languageeng
 
dc.publisherMary Ann Liebert, Inc Publishers. The Journal's web site is located at http://www.liebertpub.com/vim
 
dc.publisher.placeUnited States
 
dc.relation.ispartofViral Immunology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.rightsThis is a copy of an article published in the [Viral Immunology] © [2010] [copyright Mary Ann Liebert, Inc.]; [Viral Immunology} is available online at: http://www.liebertonline.com.
 
dc.subject.meshMembrane Glycoproteins - chemistry - immunology
 
dc.subject.meshReceptors, Virus - metabolism
 
dc.subject.meshSARS Virus - immunology
 
dc.subject.meshSevere Acute Respiratory Syndrome - immunology - prevention and control
 
dc.subject.meshViral Envelope Proteins - chemistry - immunology
 
dc.titleA 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Du, L</contributor.author>
<contributor.author>Zhao, G</contributor.author>
<contributor.author>Chan, CC</contributor.author>
<contributor.author>Li, L</contributor.author>
<contributor.author>He, Y</contributor.author>
<contributor.author>Zhou, Y</contributor.author>
<contributor.author>Zheng, BJ</contributor.author>
<contributor.author>Jiang, S</contributor.author>
<date.accessioned>2010-10-31T11:14:27Z</date.accessioned>
<date.available>2010-10-31T11:14:27Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Viral Immunology, 2010, v. 23 n. 2, p. 211-219</identifier.citation>
<identifier.issn>0882-8245</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/125154</identifier.uri>
<description.abstract>Development of vaccines is essential for the prevention of future recurrences of severe acute respiratory syndrome (SARS), caused by the SARS coronavirus (SARS-CoV). The spike (S) protein, especially receptor-binding domain (RBD) of SARS-CoV, plays important roles in the prevention of SARS infection, and is thus an important component in SARS vaccine development. In this study, we expressed a 219-mer (residues 318-536) RBD protein in Chinese hamster ovary (CHO)-K1 cells (RBD219-CHO), and tested its immune responses and protective immunity in a mouse model. The results showed that this recombinant protein was correctly folded, being able to maintain intact conformation and authentic antigenicity. It could induce strong humoral and cellular immune responses and high titers of neutralizing antibodies in the vaccinated mice. RBD219-CHO protein elicited potent protective immunity that protected all vaccinated mice from SARS-CoV challenge. These results suggest that the recombinant RBD219-CHO protein has great potential for the development of an effective and safe SARS subunit vaccine. &#169; Copyright 2010, Mary Ann Liebert, Inc..</description.abstract>
<language>eng</language>
<publisher>Mary Ann Liebert, Inc Publishers. The Journal&apos;s web site is located at http://www.liebertpub.com/vim</publisher>
<relation.ispartof>Viral Immunology</relation.ispartof>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<rights>This is a copy of an article published in the [Viral Immunology] &#169; [2010] [copyright Mary Ann Liebert, Inc.]; [Viral Immunology} is available online at: http://www.liebertonline.com.</rights>
<subject.mesh>Membrane Glycoproteins - chemistry - immunology</subject.mesh>
<subject.mesh>Receptors, Virus - metabolism</subject.mesh>
<subject.mesh>SARS Virus - immunology</subject.mesh>
<subject.mesh>Severe Acute Respiratory Syndrome - immunology - prevention and control</subject.mesh>
<subject.mesh>Viral Envelope Proteins - chemistry - immunology</subject.mesh>
<title>A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0882-8245&amp;volume=23&amp;issue=2&amp;spage=211&amp;epage=219&amp;date=2010&amp;atitle=A+219-mer+CHO-expressing+RBD+of+SARS-CoV+S+protein+induces+potent+immune+responses+and+protective+immunity</identifier.openurl>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1089/vim.2009.0090</identifier.doi>
<identifier.pmid>20374001</identifier.pmid>
<identifier.pmcid>PMC2883479</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-77953940733</identifier.scopus>
<identifier.hkuros>175102</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77953940733&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>23</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>211</identifier.spage>
<identifier.epage>219</identifier.epage>
<identifier.isi>WOS:000276413200010</identifier.isi>
<publisher.place>United States</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/125154/1/content.pdf</bitstream.url>
</item>
Author Affiliations
  1. Institute of Microbiology Chinese Academy of Sciences
  2. The University of Hong Kong
  3. New York Blood Center